Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
31,550
-500 (-1.56%)
Last updated: Jun 27, 2025
16.42%
Market Cap 432.57B
Revenue (ttm) n/a
Net Income (ttm) -35.47B
Shares Out 14.32M
EPS (ttm) -2,511.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 76,359
Average Volume 98,588
Open 32,550
Previous Close 32,050
Day's Range 31,450 - 32,750
52-Week Range 19,390 - 36,000
Beta n/a
RSI 57.39
Earnings Date Aug 13, 2025

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Employees 136
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.